A groundbreaking clinical trial at the University of Galway has successfully tested a less invasive approach to heart bypass surgery, relying solely on non-invasive cardiac-CT scan images and HeartFlow’s AI-powered blood flow analysis. Published in the European Heart Journal, the trial demonstrates the feasibility and safety of bypass surgery without invasive catheterization, offering comparable outcomes to traditional methods while potentially simplifying planning for patients undergoing surgery.
Prothea Technologies, a spin-off from the University of Edinburgh and Bath, secured €12m ($13m) in Series A financing to develop cancer diagnostics and therapeutics, addressing challenges such as inaccurate biopsies and limited treatment options for small lesions. The funding, led by European venture capital firms Earlybird Venture Capital and Mérieux Equity Partners, will support Prothea’s development of cancer management technologies, including a microendoscope combined with an image processing system for enhanced lesion visualization, and plans to start clinical trials for cancer imaging, biopsy, and laser ablation treatment.
Biotronik’s latest insertable cardiac monitor (ICM), BioMonitor IV, has received CE mark approval and completed its first European implant, boasting AI capabilities for false positive reduction across major arrhythmias. With features like SmartECG for reducing false detections by 86% while maintaining 98% clinically relevant episodes, along with PVC and PAC discrimination capabilities, BioMonitor IV marks a significant advancement in cardiac monitoring technology, as showcased at the EHRA Congress in Berlin.
Steris, after acquiring Cantel’s dental business in 2021, is now planning to sell the segment. Peak Rock Capital has agreed to pay an additional $12.5 million if the dental business meets certain revenue targets in fiscal year 2025, with Steris aiming to close the sale in the first quarter of its 2025 fiscal year.
Bosch Healthcare and Randox will invest $159m to expand Bosch’s Vivalytic analysis platform, focusing on joint research, development, and sales efforts for new tests, including a rapid sepsis test, for the point-of-care molecular diagnostic device. The partnership aims to revolutionize sepsis diagnosis, potentially improving treatment outcomes and lowering mortality rates, building on their previous collaboration in creating a fully automated PCR test for the SARS-CoV-2 coronavirus during the Covid-19 pandemic.
ThinkMedTek 
Leave a comment